The OECI and EurocanPlatform
21 May 2012
The OECI and EurocanPlatform
Problems in the structure of clinical trials
Heterogeneity of global cancer outcomes
New approaches to personalised medicine
Recent developments in neoadjuvant therapy
Highlights and goals of IMPAKT 2012
PI3K and the heterogeneity of small tumour breast cancer
Molecularly characterising triple negative breast cancer
Endocrine therapy and endocrine resistant breast cancer
Neoadjuvant therapy and PCR through chemotherapy prior to surgery
Minimising recurrence by using most effective treatment
Targeting the PI3K/mTOR pathway